Assertio Holdings, Inc. (ASRT)
ASRT Stock Price Chart
Explore Assertio Holdings, Inc. interactive price chart. Choose custom timeframes to analyze ASRT price movements and trends.
ASRT Company Profile
Discover essential business fundamentals and corporate details for Assertio Holdings, Inc. (ASRT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Dec 1997
Employees
58.00
Website
https://www.assertiotx.comCEO
Brendan P. O'Grady
Description
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
ASRT Financial Timeline
Browse a chronological timeline of Assertio Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 10 Nov 2025
EPS estimate is -$0.08, while revenue estimate is $27.02M.
Earnings released on 11 Aug 2025
EPS came in at -$0.17 falling short of the estimated -$0.10 by -70.00%, while revenue for the quarter reached $29.22M , missing expectations by -0.28%.
Earnings released on 12 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.06 by -133.33%, while revenue for the quarter reached $26.49M , missing expectations by -3.75%.
Earnings released on 12 Mar 2025
EPS came in at -$0.11 falling short of the estimated -$0.05 by -120.00%, while revenue for the quarter reached $32.18M , beating expectations by +5.52%.
Earnings released on 11 Nov 2024
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $29.20M , beating expectations by +1.85%.
Earnings released on 7 Aug 2024
EPS came in at -$0.04 falling short of the estimated -$0.03 by -25.00%, while revenue for the quarter reached $31.13M , beating expectations by +3.48%.
Earnings released on 6 May 2024
EPS came in at $0.04 falling short of the estimated $0.12 by -66.67%, while revenue for the quarter reached $32.45M , beating expectations by +9.96%.
Earnings released on 11 Mar 2024
EPS came in at $0.11 surpassing the estimated -$0.00 by +2.95K%, while revenue for the quarter reached $32.99M , missing expectations by -2.44%.
Earnings released on 8 Nov 2023
EPS came in at $0.01 falling short of the estimated $0.14 by -92.86%, while revenue for the quarter reached $35.63M , beating expectations by +1.16%.
Earnings released on 3 Aug 2023
EPS came in at $0.13 falling short of the estimated $0.14 by -7.14%, while revenue for the quarter reached $40.99M , beating expectations by +0.35%.
Earnings released on 9 May 2023
EPS came in at -$0.07 falling short of the estimated $0.13 by -153.85%, while revenue for the quarter reached $42.47M , beating expectations by +12.82%.
Earnings released on 8 Mar 2023
EPS came in at $1.34 surpassing the estimated $0.48 by +179.17%, while revenue for the quarter reached $50.35M , beating expectations by +6.14%.
Earnings released on 8 Nov 2022
EPS came in at $0.08 surpassing the estimated $0.07 by +14.29%, while revenue for the quarter reached $34.21M , beating expectations by +9.10%.
Earnings released on 8 Aug 2022
EPS came in at $0.16 surpassing the estimated $0.08 by +100.00%, while revenue for the quarter reached $35.13M , beating expectations by +10.54%.
Earnings released on 9 May 2022
EPS came in at $0.20 surpassing the estimated $0.09 by +122.22%, while revenue for the quarter reached $36.54M , beating expectations by +11.86%.
Earnings released on 9 Mar 2022
EPS came in at $0.10 falling short of the estimated $0.12 by -16.67%, while revenue for the quarter reached $33.33M , beating expectations by +9.73%.
Earnings released on 4 Nov 2021
EPS came in at $0.08 surpassing the estimated $0.02 by +300.00%, while revenue for the quarter reached $25.47M , beating expectations by +15.57%.
Earnings released on 5 Aug 2021
EPS came in at -$0.32 falling short of the estimated -$0.08 by -300.00%, while revenue for the quarter reached $25.37M , meeting expectations.
Stock split effective on 18 May 2021
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 May 2021
EPS came in at $0.16 surpassing the estimated $0.08 by +100.00%, while revenue for the quarter reached $26.84M , missing expectations by -9.09%.
Earnings released on 11 Mar 2021
EPS came in at $0.12 , while revenue for the quarter reached $30.18M .
Earnings released on 6 Nov 2020
EPS came in at $0.08 surpassing the estimated -$0.03 by +399.96%, while revenue for the quarter reached $34.57M , missing expectations by -77.78%.
ASRT Stock Performance
Access detailed ASRT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.